@article{3477f36358f44f84af46141bce4e684e,
title = "Genomic analysis of carbapenem-resistant Pseudomonas aeruginosa ST143 clone showing susceptibility to broad-spectrum cephalosporins",
abstract = "Objectives: Using whole-genome sequencing (WGS), we aimed to characterise a Pseudomonas aeruginosa ST143 clinical strain (Pb9) that presented resistance to meropenem and imipenem and susceptibility to piperacillin/tazobactam and broad-spectrum cephalosporins. Methods: The antimicrobial susceptibility profile was confirmed by broth microdilution. WGS was performed using an Illumina MiSeq platform to identify possible genetic determinants of β-lactam resistance. Transcription levels of chromosomally encoded efflux systems and oprD were evaluated by RT-qPCR. Results: WGS analysis showed that no acquired carbapenemase-encoding gene was found in isolate Pb9, although mutations in the chromosomally encoded β-lactamase genes blaOXA-488, blaPIB-1 and blaPDC-5 were observed. In addition, we detected a premature stop codon in the major porin-encoding gene oprD coupled with hyperexpression of MexAB–OprM and MexEF–OprN. Conclusion: Our results suggest that the β-lactam resistance phenotype presented by strain Pb9 might be related to an association of OprD loss with hyperexpression of the efflux pump systems MexAB–OprM and MexEF–OprN. However, the contribution of OXA-488, PDC-5 and PIB-1 to this phenotype remains unclear and warrants further investigation.",
keywords = "Carbapenem resistance, Genome, Non-fermenting Gram-negative bacilli, OXA-50, PDC-5, Pseudomonas, Genomics, Pseudomonas aeruginosa/genetics, Anti-Bacterial Agents/pharmacology, Microbial Sensitivity Tests, Cephalosporins/pharmacology, Clone Cells, Meropenem",
author = "Streling, {Ana Paula} and Rodrigo Cay{\^o} and Nodari, {Carolina S.} and Almeida, {Luiz G.P.} and Santos, {Fernanda F.} and Blake Hanson and Dinh, {An Q.} and Vasconcelos, {Ana Tereza R.} and Miller, {Willian R.} and Arias, {Cesar A.} and Gales, {Ana C.}",
note = "Funding Information: The authors are grateful to the Coordena{\c c}{\~a}o de Aperfei{\c c}oamento de Pessoal de N{\'i}vel Superior (CAPES) for providing grants to APS, CSN and FFS (CAPES-PNPD), and to the National Council for Science and Technological Development (CNPq) for providing grants to ATRV and ACG [Process number: 312066/2019-8]. Funding Information: Competing interests: ACG has recently received research funding and/or consultation fees from Bayer, Crist{\'a}lia, InfectoPharm, Enthasis, Eurofarma, MSD, Pfizer and Zambon; CAA has received grants from Merck, MeMed Diagnostics and Entasis Pharmaceuticals and has also received chapter royalties from UptoDate, Harrison's Principles of Internal Medicine, Mandell's Principles and Practice of Infectious Diseases, study section member/grant reviewer fees from NIH/NIAID, travel fees from the Infectious Diseases Society of America (IDSA) and American Society for Microbiology, and an Antimicrobial Agents and Chemotherapy Editor's stipend from the American Society for Microbiology, all outside the submitted work; WRM has received grants and/or honoraria from NIH/NIAID, Merck, Entasis, Achaogen, IDSA and Shionogi. All other authors declare no competing interests. This study was not financially supported by any diagnostic/pharmaceutical company. Funding Information: The authors are grateful to the Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior (CAPES) for providing grants to APS, CSN and FFS (CAPES-PNPD), and to the National Council for Science and Technological Development (CNPq) for providing grants to ATRV and ACG [Process number: 312066/2019-8]. Competing interests: ACG has recently received research funding and/or consultation fees from Bayer, Crist?lia, InfectoPharm, Enthasis, Eurofarma, MSD, Pfizer and Zambon; CAA has received grants from Merck, MeMed Diagnostics and Entasis Pharmaceuticals and has also received chapter royalties from UptoDate, Harrison's Principles of Internal Medicine, Mandell's Principles and Practice of Infectious Diseases, study section member/grant reviewer fees from NIH/NIAID, travel fees from the Infectious Diseases Society of America (IDSA) and American Society for Microbiology, and an Antimicrobial Agents and Chemotherapy Editor's stipend from the American Society for Microbiology, all outside the submitted work; WRM has received grants and/or honoraria from NIH/NIAID, Merck, Entasis, Achaogen, IDSA and Shionogi. All other authors declare no competing interests. This study was not financially supported by any diagnostic/pharmaceutical company. Ethical approval: Not required. Publisher Copyright: {\textcopyright} 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = sep,
doi = "10.1016/j.jgar.2021.05.019",
language = "English (US)",
volume = "26",
pages = "177--179",
journal = "Journal of Global Antimicrobial Resistance",
issn = "2213-7165",
publisher = "Elsevier BV",
}